ResMed Reports Q1 2027 Revenue Growth and Increased EPS Guidance
ResMed (RMD) reported strong first-quarter fiscal 2027 results, with revenue reaching $1.415 billion, a 6% increase year-over-year. This growth was driven by robust global demand for sleep and breathing solutions, particularly in the Americas and international markets like France. Non-GAAP diluted earnings per share rose 14% to $2.91, supported by gross margin expansion to 62.5% due to manufacturing and procurement efficiencies. The company provided optimistic full-year guidance, projecting non-GAAP EPS between $12.00 and $12.25. Despite these gains, management noted potential headwinds including inflation in electronic components and a projected deceleration in the 'Rest of World' sleep device segment following the conclusion of a fleet renewal in France. ResMed also continues to invest heavily in R&D and automation to expand global manufacturing capacity.
Tickers: $RMD
Topics: EPS Increase Financial Guidance Gross Margin Expansion Revenue Growth Share Repurchases